Protalix: Corporate Presentation (Protalix) - Jan 23, 2016 - "OPRX 106 Phase I – Results"; "Safety: OPRX-106 was safe and well tolerated"; “Immunomodulation: Regulatory T cell activation showed biological activity in the gut CD4/CD25, CD4/Foxp3/CD25, CD8/CD25, CD8/Foxp3/CD25), Alteration of systemic immune system without significant systemic absorption"; "Serum cytokine levels remained stable"
P1 data • Biosimilar
|